Literature DB >> 18220605

The potential role of thiamine (vitamin B1) in diabetic complications.

Paul J Thornalley1.   

Abstract

Accumulation of triosephosphates arising from high cytosolic glucose concentrations in hyperglycemia is one likely or potential trigger for biochemical dysfunction leading to the development of diabetic complications. This may be prevented by disposal of excess triosephosphates via the reductive pentosephosphate pathway. This pathway is impaired in experimental and clinical diabetes by mild thiamine deficiency. The expression and activity of the thiamine-dependent enzyme, transketolase--the pacemaking enzyme of the reductive pentosephosphate pathway, is consequently decreased. Correction of thiamine deficiency in experimental diabetes by high dose therapy with thiamine and the thiamine monophosphate prodrug, Benfotiamine, restores disposal of triosephosphates by the reductive pentosephosphate pathway in hyperglycemia. This prevented multiple mechanisms of biochemical dysfunction: activation of protein kinase C, activation of the hexosamine pathway, increased glycation and oxidative stress. Consequently, the development of incipient diabetic nephropathy, neuropathy and retinopathy were prevented. Both thiamine and Benfotiamine produced other remarkable effects in experimental diabetes: marked reversals of increased diuresis and glucosuria without change in glycemic status. High dose thiamine also corrected dyslipidemia in experimental diabetes--normalizing cholesterol and triglycerides. Dysfunction of beta-cells and impaired glucose tolerance in thiamine deficiency and suggestion of a link of impaired glucose tolerance with dietary thiamine indicates that thiamine therapy may have a future role in prevention of type 2 diabetes. More immediately, given the emerging multiple benefits of thiamine repletion, even mild thiamine deficiency in diabetes should be avoided and thiamine supplementation to high dose should be considered as adjunct nutritional therapy to prevent dyslipidemia and the development of vascular complications in clinical diabetes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 18220605     DOI: 10.2174/157339905774574383

Source DB:  PubMed          Journal:  Curr Diabetes Rev        ISSN: 1573-3998


  41 in total

1.  Therapy: Vitamin B6, B9 and B12 in diabetic nephropathy--beware.

Authors:  Paul J Thornalley; Naila Rabbani
Journal:  Nat Rev Endocrinol       Date:  2010-09       Impact factor: 43.330

2.  Pharmacokinetics of high-dose oral thiamine hydrochloride in healthy subjects.

Authors:  Howard A Smithline; Michael Donnino; David J Greenblatt
Journal:  BMC Clin Pharmacol       Date:  2012-02-04

3.  The relationship between lactate and thiamine levels in patients with diabetic ketoacidosis.

Authors:  Ari Moskowitz; Amanda Graver; Tyler Giberson; Katherine Berg; Xiaowen Liu; Amy Uber; Shiva Gautam; Michael W Donnino
Journal:  J Crit Care       Date:  2013-08-28       Impact factor: 3.425

4.  Anti-inflammatory effects of benfotiamine are mediated through the regulation of the arachidonic acid pathway in macrophages.

Authors:  Mohammad Shoeb; Kota V Ramana
Journal:  Free Radic Biol Med       Date:  2011-10-24       Impact factor: 7.376

Review 5.  Oxidative stress and diabetic complications.

Authors:  Ferdinando Giacco; Michael Brownlee
Journal:  Circ Res       Date:  2010-10-29       Impact factor: 17.367

6.  Triglyceride, nonesterified fatty acids, and prediabetic neuropathy: role for oxidative-nitrosative stress.

Authors:  Sergey Lupachyk; Pierre Watcho; Nailia Hasanova; Ulrich Julius; Irina G Obrosova
Journal:  Free Radic Biol Med       Date:  2012-02-04       Impact factor: 7.376

7.  Increased protein damage in renal glomeruli, retina, nerve, plasma and urine and its prevention by thiamine and benfotiamine therapy in a rat model of diabetes.

Authors:  N Karachalias; R Babaei-Jadidi; N Rabbani; P J Thornalley
Journal:  Diabetologia       Date:  2010-04-06       Impact factor: 10.122

Review 8.  Pharmacological treatment of diabetic neuropathic pain.

Authors:  Howard S Smith; Charles E Argoff
Journal:  Drugs       Date:  2011-03-26       Impact factor: 9.546

9.  High-dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double-blind placebo-controlled pilot study.

Authors:  N Rabbani; S S Alam; S Riaz; J R Larkin; M W Akhtar; T Shafi; P J Thornalley
Journal:  Diabetologia       Date:  2008-12-05       Impact factor: 10.122

10.  High-dose thiamine supplementation improves glucose tolerance in hyperglycemic individuals: a randomized, double-blind cross-over trial.

Authors:  F Alaei Shahmiri; M J Soares; Y Zhao; J Sherriff
Journal:  Eur J Nutr       Date:  2013-05-29       Impact factor: 5.614

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.